REGN
KNSAsupplier · Not moving with the group now
Filing receipt · REGN / KNSA
“Pursuant to the Regeneron Agreement, we have entered into a supply agreement with Regeneron to purchase both clinical and commercial product.”
KNSA · supplier
Confirmed
Biotech Rare Diseases
2 names are moving together; 0% are participating in the current session.
2 observed daily builds
Co-movement
Observed member paths adjusted against SPY. Shading marks the latest observation window.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals Interna | Healthcare | -1.3% | Group member |
| CRNX | Crinetics Pharmaceuticals, Inc. | Healthcare | +0.3% | Most structurally connected |
Why we believe this
Cohort
2 namesParticipation
0% this sessionObserved history
2 daily buildsThis identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Connected, outside the group
CORT
KNSAtext peer · Not moving with the group now
No filing excerpt is available for this relationship.
LLY
CRNXpartner · Not moving with the group now
Filing receipt · LLY / CRNX
“In July 2024, Radionetics formed a strategic partnership with Eli Lilly and Company (“Lilly”), receiving a $ 140.0 million upfront payment and granting Lilly the exclusi…”
CRNX · partner
GPCR
CRNXtext peer · Not moving with the group now
No filing excerpt is available for this relationship.
HRMY
CRNXtext peer · Current intraday read unavailable
No filing excerpt is available for this relationship.
History
2026-07-292 names in the durable cohort
2026-07-282 names in the durable cohort